Browse by Person

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Jump to: Article
Number of items: 4.

Article

Schöffski, P, Wozniak, A, Stacchiotti, S et al. (20 more authors) (2019) Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’. Annals of Oncology, 30 (2). p. 344. ISSN 0923-7534

Touati, N, Schöffski, P, Litière, S et al. (11 more authors) (2018) European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy. Clinical Oncology, 30 (7). pp. 448-454. ISSN 0936-6555

Schöffski, P, Wozniak, A, Kasper, B et al. (23 more authors) (2018) Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’. Annals of Oncology, 29 (3). pp. 758-765. ISSN 0923-7534

Schöffski, P, Wozniak, A, Stacchiotti, S et al. (20 more authors) (2017) Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’. Annals of Oncology, 28 (12). pp. 3000-3008. ISSN 0923-7534

This list was generated on Sun Aug 9 19:39:20 2020 BST.